Several other institutional investors have also modified their holdings of ALXN. Jennison Associates LLC boosted its position in shares of Alexion Pharmaceuticals by 720.0% in the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after buying an additional 4,682,336 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Alexion Pharmaceuticals by 4,509.0% in the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after buying an additional 864,967 shares during the period. Alkeon Capital Management LLC acquired a new stake in shares of Alexion Pharmaceuticals in the third quarter worth $70,145,000. Wells Fargo & Company MN boosted its position in shares of Alexion Pharmaceuticals by 32.7% in the third quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock worth $218,647,000 after buying an additional 383,713 shares during the period. Finally, Pictet Asset Management Ltd. boosted its position in shares of Alexion Pharmaceuticals by 46.7% in the third quarter. Pictet Asset Management Ltd. now owns 1,126,275 shares of the biopharmaceutical company’s stock worth $158,005,000 after buying an additional 358,695 shares during the period. 94.01% of the stock is owned by institutional investors and hedge funds.

Get Alexion Pharmaceuticals alerts:

In other Alexion Pharmaceuticals news, CFO Paul J. Clancy sold 6,079 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $707,048.49. Following the transaction, the chief financial officer now directly owns 95,093 shares in the company, valued at $11,060,266.83. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares in the company, valued at $4,399,600.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,930 shares of company stock worth $3,378,199. Corporate insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $113.97 on Wednesday. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $25,588.69, a PE ratio of 58.15, a price-to-earnings-growth ratio of 1.08 and a beta of 1.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. During the same period last year, the company earned $1.26 earnings per share. The business’s revenue was up 9.5% compared to the same quarter last year. equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 5.87 EPS for the current year.

Several analysts recently issued reports on ALXN shares. Evercore ISI upgraded Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a report on Monday, February 5th. Leerink Swann cut their price objective on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating for the company in a report on Friday, February 9th. Raymond James Financial reiterated an “outperform” rating and set a $130.00 price objective (down from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada increased their price objective on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Finally, TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $152.77.

COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2018/02/14/ken-stern-associates-inc-trims-stake-in-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).